MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Chitomur Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Chitomur (Bladder Cytomax A-12) is a natural Khavinson peptide bioregulator: a lyophilized complex of short peptides isolated from animal urinary-bladder tissue. Rather than binding a surface receptor, these ultrashort peptides are hypothesized to enter the nucleus of bladder cells and bind specific DNA promoter sequences, nudging bladder-wall and detrusor gene expression toward a younger, better-regenerating state (PMID 34834147, 25761685). The strongest clinical signal is a 30-day blind randomized placebo-controlled trial in elderly men with benign prostatic hyperplasia, in which Chitomur significantly improved urination and quality of life with no adverse effects (PMID 24640697). It is sold as an oral 10 mg capsule (and sublingual form), dosed at roughly 10-40 mg/day for 30-day courses repeated every few months. The subcutaneous reference protocol here is an educational reconstitution convention: dissolve a 10 mg vial in 2 mL bacteriostatic water (5 mg/mL) so a 1-2 mg dose is 20-40 units on a U-100 syringe. This is reference information, not medical advice.
Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
Typical dose: 10-40 mg/day orally (10 mg capsules)
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.0500 mg (50 mcg) on a U-100 insulin syringe.
Storage: Capsules: store in a cool, dry place at room temperature, away from light and humidity. For the educational injectable model: keep the lyophilized vial frozen at -20 °C for long-term storage or at 2-8 °C for short periods; once reconstituted, refrigerate at 2-8 °C and use within about 3-4 weeks.
Half-life: Not formally characterized; the intact short peptides are likely hydrolyzed within minutes, with effects attributed to downstream bladder gene-expression changes that outlast the peptide.
Route: Clinically oral 10 mg capsules (and a sublingual form); this page models a once-daily subcutaneous reconstitution reference, a route not validated for Chitomur.
Status: Not FDA or EMA approved; a Khavinson bladder bioregulator sold as a supplement / research compound, with only one small controlled human trial.
About Chitomur
Chitomur is a bladder-targeted Khavinson peptide bioregulator: a natural "Cytomax" complex of short peptides extracted from animal urinary-bladder tissue and studied for its proposed ability to normalize bladder gene expression and urination in aging [1][2]. In real-world use this is an ORAL product, sold as 10 mg capsules (and, more recently, a sublingual form); clinically it is swallowed on an empty stomach, and the subcutaneous figures below are an educational reconstitution reference modeled on a 10 mg lyophilized vial, not a route that has been validated for Chitomur. The only controlled human data is a small 30-day blind randomized placebo-controlled trial in elderly men with benign prostatic hyperplasia, so every dose here should be read as illustrative reference information rather than therapeutic guidance [1].\n\nEducational guide for reconstitution and short-course dosing.\n\nFrequency: Inject once daily subcutaneously during a short course of roughly 30 days, with courses typically repeated as maintenance pulses every 2 to 3 months in the bioregulator literature [3]. Reconstituting a 10 mg vial with 2 mL of bacteriostatic water yields 5 mg/mL, so the educational 1-2 mg daily reference corresponds to 20-40 units on a U-100 insulin syringe. The crude oral capsule dose (10-40 mg/day) is far higher than this purified injectable reference because oral peptide complexes have low bioavailability and most of the capsule mass is inactive carrier peptide.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe.
Inject it slowly down the inner wall of the 10 mg Chitomur vial; do not spray it directly onto the lyophilized powder.
Gently swirl or roll the vial until the powder fully dissolves into a clear solution; never shake, which can shear the peptide and cause foaming.
The result is 5 mg/mL, so 1 mg is 20 units (0.2 mL) and 2 mg is 40 units (0.4 mL) on a U-100 insulin syringe; swab the stopper and draw your daily dose.
Inject subcutaneously once daily during the course, store the vial refrigerated at 2-8 °C between uses, and discard after the stability window (about 3-4 weeks).
Interactive Chitomur Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 2mL water yields 5.00 mg/mL. To evaluate a 250mcg dose, pull to 5.0 units (5 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Conservative course (once daily, days 1-30) | 1000 mcg (1 mg) | 20 units (0.20 mL) |
| Standard course (once daily, days 1-30) | 2000 mcg (2 mg) | 40 units (0.40 mL) |
| Maintenance pulse (once daily, 10-day cycles every 2-3 months) | 1000 mcg (1 mg) | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Chitomur, 10 mg each):
- checkOne 30-day course at the conservative 1 mg/day SC reference uses 3 vials (30 mg); the standard 2 mg/day course uses about 6 vials.
- check8-week window at 1 mg/day: about 6 vials.
- check12-week window at 1 mg/day: about 9 vials.
- check16-week window at 1 mg/day: about 12 vials (double these counts at the standard 2 mg/day).
Insulin Syringes (U-100):
- checkOne 0.3 mL (30-unit) syringe per daily injection, since doses fall at 20-40 units.
- check8-week window: about 56 syringes.
- check12-week window: about 84 syringes.
- check16-week window: about 112 syringes.
Bacteriostatic Water (30 mL bottles): Use 2 mL per vial for reconstitution.
- checkEach reconstituted 10 mg vial consumes 2 mL of bacteriostatic water.
- checkA 16-week course at 1 mg/day uses about 12 vials, or roughly 24 mL, so a single 30 mL bottle covers the whole window.
- checkDiscard any vial not used within its 3-4 week stability window rather than over-diluting to extend it.
Alcohol Swabs: clean the vial stopper and injection site before each use.
- checkUse 2 swabs per injection (vial top plus skin).
- check8-week window: about 112 swabs; 12-week window: about 168 swabs; 16-week window: about 224 swabs.
- checkA pair of 100-count boxes comfortably covers a full 16-week course.
Mechanism of Action (MOA)
Chitomur is a member of the Khavinson "Cytomax" class: a natural peptide bioregulator obtained by isolating low-molecular-weight peptide fractions from the urinary-bladder tissue of young animals at the St. Petersburg Institute of Bioregulation and Gerontology [3][6]. Unlike conventional peptide hormones, these ultrashort 2-to-4-residue peptides are not thought to act on cell-surface receptors. The prevailing hypothesis is that they are small and charged enough to enter the cytoplasm and nucleus of bladder epithelial and detrusor smooth-muscle cells, where they bind specific 3-to-6-nucleotide sequences in gene promoter regions, locally destabilize the DNA double helix, and modulate transcription of a defined, tissue-appropriate set of genes [2][4][7]. Because age-related loss of CpG methylation makes promoter DNA more accessible, the model holds that these peptides preferentially re-activate transcription programs that have been silenced with age, behaving as epigenetic-style regulators rather than signaling ligands [4][5].\n\nFor Chitomur, the target organ is the bladder, and the proposed downstream effects include support of urothelial regeneration, detrusor contractile protein synthesis, microvascular tone, and antioxidant defense in the bladder wall, which is the mechanistic rationale offered for improved urination in older adults [1][8]. It is important to stress that this evidence is largely preclinical, in vitro, or drawn from small Russian clinical observations, and originates predominantly from a single research lineage; no independent Western human pharmacology of Chitomur exists.\n\nPharmacokinetics have not been formally characterized. As small, unmodified peptides, the active fractions are expected to be hydrolyzed rapidly by gastrointestinal, plasma, and tissue peptidases, giving a free-peptide half-life on the order of minutes; any durable effect is attributed to changes in gene expression that outlast the peptide itself, which is why these bioregulators are given in short 30-day courses repeated seasonally rather than continuously [2][3]. Oral bioavailability of intact peptide is low because of proteolysis, so the crude capsule must deliver a relatively large 10 mg mass to land a small bioactive fraction at the tissue.\n\nClinically and historically Chitomur is delivered as oral capsules (10 mg each; "intensive" courses of about 10-40 mg/day, or 1-4 capsules, for 30 days) and, more recently, as a sublingual preparation; the once-daily subcutaneous reconstitution described on this page is an educational modeling convention, not a route validated for this cytomax [1]. Reconstituting a 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL, so the illustrative 1-2 mg reference dose is 20-40 units on a U-100 syringe. The purified injectable reference is deliberately far smaller than the crude oral dose because most of the capsule mass is inactive carrier peptide. Chitomur remains an unapproved supplement/research compound, and the dosing here is reference information only, not therapeutic guidance.
Clinical Trial Efficacy Highlights
- starThe most direct evidence is a blind, randomized, placebo-controlled study by Gomberg, Ryzhak, and Liutov (2013) in Advances in Gerontology, in which a 30-day course of the bladder peptide bioregulator Chitomur significantly improved basic urination parameters, urodynamics, and quality of life in elderly and senile men (ages 62-83) with benign prostatic hyperplasia, with the benefit persisting for a month after treatment and no adverse effects observed [1].
- starA 2024 review in Urologiia by Gadzhieva on the use of bioregulatory peptides in prostate and lower-urinary-tract disease situates bladder-targeted peptide bioregulators such as Chitomur within current Russian urological practice, while still reflecting a literature dominated by small or open-label studies [8].
- starKhavinson, Kuznik, and Ryzhak (2012) summarized the experimental basis for peptide bioregulators as a new class of geroprotectors, reporting effects on tissue-specific gene expression, organ regeneration, and lifespan extension in animal models that underpin the Cytomax concept Chitomur belongs to [3].
- starThe 2021 Molecules systematic review by Khavinson and colleagues catalogues how 2-to-7-residue peptides, including organ-specific sequences, regulate tissue-targeted gene expression and protein synthesis, providing the mechanistic framework for Chitomur but reporting no bladder-specific human efficacy data [2].
- starAshapkin, Linkova, Khavinson, and Vanyushin (2015) described, in Biochemistry (Moscow), epigenetic mechanisms by which short peptides change gene-promoter methylation and expression during aging of human cells, lending laboratory plausibility to the gene-regulation model invoked for Chitomur [4].
- starAn independent 2019 review in Clinical Epigenetics by Janssens and colleagues catalogued Khavinson di- to tetrapeptides among endogenous peptides that can act as epigenetic modulators and DNA-methylation inhibitors, situating the Cytomax mechanism within an externally authored literature [5].
- starFedoreyeva and colleagues (2011) showed with fluorescence-labeled Khavinson peptides that such short peptides penetrate the cytoplasm, nucleus, and nucleolus of cultured human cells and bind specific DNA oligonucleotide sequences in vitro, supporting the nuclear DNA-binding mechanism proposed for bladder peptides like Chitomur [7].
- starAt the class level, a 15-year randomized follow-up by Korkushko, Khavinson, and colleagues found that a pineal peptide geroprotector slowed aging and lowered mortality in elderly patients; this is the strongest long-term clinical signal for the Khavinson peptide family, but it studied a different peptide and cannot be extrapolated to Chitomur [9].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningThe only controlled human safety data is the small 30-day BPH trial, which reported no adverse effects [1]; beyond that, Chitomur's long-term and systemic safety profile is essentially uncharacterized.
- warningTaken orally, peptide bioregulators are generally reported by suppliers to cause only infrequent mild gastrointestinal discomfort, but these figures come from marketing materials rather than independent trials and should be treated cautiously.
- warningIn the educational subcutaneous model, injection can cause local reactions including redness, itching, swelling, bruising, or transient pain at the injection site.
- warningBecause Chitomur is a natural complex extracted from bovine/animal bladder tissue, there is a theoretical risk of immune or hypersensitivity reactions and of tissue-derived contaminants; stop use and seek care for rash, hives, facial or throat swelling, or difficulty breathing.
- warningResearch- and supplement-grade peptide products are not manufactured to pharmaceutical standards, so contamination, endotoxin, inconsistent peptide content, and inaccurate labeling are realistic risks; sterility and purity cannot be assumed.
- warningThere are no formal drug-interaction studies; people taking medications for the bladder, prostate, or other conditions should not assume Chitomur is inert or compatible, and undiagnosed urinary symptoms (especially hematuria) should be evaluated by a clinician before self-treating.
- warningChitomur has not been evaluated in pregnancy, breastfeeding, in children, or in people with active bladder or prostate malignancy, and should be avoided in these groups.
- warningRegulatory status: Chitomur is not approved by the FDA, EMA, or other major regulators as a drug; it is sold as a dietary supplement / research bioregulator, and nothing here should be read as a claim that it treats any disease.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Chitomur dosage?expand_more
There is no rigorously validated clinical dose, but the most commonly cited Chitomur dosage is oral: each capsule contains 10 mg of the bladder peptide complex, and an 'intensive' course is roughly 10-40 mg/day (1 to 4 capsules) taken on an empty stomach for 30 days, followed by a lower maintenance pulse of about 10 mg every few days, repeated every 2-3 months. The one controlled study, a 30-day blind randomized placebo-controlled trial in elderly men with benign prostatic hyperplasia, supports the course concept but did not establish a precise optimal dose. The subcutaneous 1-2 mg/day figures on this page are an educational reconstitution reference, not a therapeutic recommendation.
Is Chitomur FDA approved?expand_more
No. Chitomur is not approved by the FDA, the EMA, or any other major Western regulator as a drug. It originates from the Khavinson peptide-bioregulator program in Russia and is sold as a dietary supplement or research bioregulator. Apart from one small 30-day Russian trial in benign prostatic hyperplasia, there are no large, independent, peer-reviewed clinical trials. Nothing on this page is a claim that Chitomur is safe or effective for treating any condition, and it is not a substitute for evaluation of urinary symptoms by a qualified clinician.
How do you reconstitute Chitomur for the educational injectable model?expand_more
Clinically Chitomur is an oral capsule, so reconstitution is only an educational modeling convention used on this site. To follow it, draw 2 mL of bacteriostatic water and inject it slowly down the inner wall of a 10 mg vial, then swirl gently (never shake) until the powder dissolves into a clear solution. This gives 5 mg/mL, so 1 mg is 20 units (0.2 mL) and 2 mg is 40 units (0.4 mL) on a U-100 insulin syringe. Keep the vial refrigerated at 2-8 °C and discard after about 3-4 weeks. This Chitomur reconstitution math is reference information only.
What is Chitomur's half-life?expand_more
Chitomur's half-life has not been formally characterized in published pharmacokinetic studies. As a complex of small, unmodified peptides, the intact molecules are expected to be broken down rapidly by gastrointestinal, plasma, and tissue peptidases, giving a free-peptide half-life on the order of minutes. The Khavinson framework attributes any longer-lasting effect to downstream changes in bladder-tissue gene expression that outlast the peptide itself, which is why the bioregulators are dosed in short 30-day courses repeated every few months rather than continuously.
Can Chitomur be stacked with other Khavinson bioregulators, and is it taken orally or by injection?expand_more
In real-world use Chitomur is taken orally as 10 mg capsules (or sublingually), not by injection; the subcutaneous protocol here is an educational reference only. In the bioregulator literature, tissue-specific Cytomaxes are commonly combined, and Chitomur is often marketed alongside prostate, kidney, and vascular peptides for the urinary system. However, there are no controlled data on the safety, interactions, or added benefit of any such stack, and combining unapproved peptide products multiplies the unknown risks. This is general information, not medical advice.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Chitomur, plus the universal dosing calculator.
Academic References & Study Citations
Gomberg VG, Ryzhak VG, Liutov RV. [Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia]. Adv Gerontol (Uspekhi Gerontologii). 2013;26(3):476-480. (Blind randomized placebo-controlled study of the bladder peptide bioregulator Chitomur.) View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies]. Adv Gerontol (Uspekhi Gerontologii). 2012;25(4):696-708. View Scientific Paper →
Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015;80(3):310-322. View Scientific Paper →
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11(1):101. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. View Scientific Paper →
Gadzhieva ZK. [Possibilities of using bioregulatory peptide in prostate diseases]. Urologiia (Moscow). 2024;(4):138-143. View Scientific Paper →
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. View Scientific Paper →